Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 12/20 | 0.52 |
| ▸ | PROKR1 | Q8TCW9 | 12/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3973906 | 0.82 | KDM4E (0.49) | FPR2PROKR1HRH3ALDH1A1EGFR | |
| SCHEMBL6104309 | 0.81 | FPR2 (0.53) | FPR2PROKR1 | |
| SCHEMBL5864825 | 0.80 | ALDH1A1 (0.51) | FPR2PROKR1SMN1; SMN2CYP2D6MMP13 | |
| SCHEMBL25769675 | 0.80 | CSNK2A1 (0.54) | ALDH1A1 | |
| SCHEMBL5864797 | 0.79 | RORC (0.50) | PDE4BEGFR | |
| SCHEMBL16038107 | 0.79 | HRH3 (0.56) | FPR2PROKR1SMN1; SMN2CYP2D6HRH3 | |
| SCHEMBL5865374 | 0.78 | HRH3 (0.47) | HRH3 | |
| SCHEMBL5864721 | 0.78 | SCN8A (0.49) | HRH3ALDH1A1 | |
| SCHEMBL3121093 | 0.78 | CSNK2A1 (0.46) | FPR2PROKR1HRH3ALDH1A1 | |
| SCHEMBL5864782 | 0.78 | HRH3 (0.48) | FPR2PROKR1SMN1; SMN2HRH3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030138-B2 | Benzamidine derivatives | SANKYO COMPANY, LIMITED (JP) | 2006-04-18 | — | — | US | disclosed |
| US-20040147555-A1 | Benzamidine derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-07-29 | — | — | US | disclosed |
| EP-1375482-A1 | BENZAMIDINE DERIVATIVE | Sankyo Company, Limited (JP) | 2004-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147555-A1 | Benzamidine derivatives | F9, F7, F2 | FPR2 1184/4885PROKR1 1559/4885SMN1; SMN2 4174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.